Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycles) product platform, announced that Chief Executive Officer Kevin Lee, Ph.D., will give a presentation at the Delivery of Novel Therapies in the 21st Century conference, hosted by the Royal Society and Academy of Medical Sciences FORUM programme.
Dr. Lee will describe Bicycles breakthrough technology as well as its progress in advancing its robust pipeline of preclinical and clinical therapeutics for cancer and other diseases.
The conference will be held on October 24-25, 2018 at the Royal Society in London.
About Bicycle Therapeutics
Bicycle Therapeutics is developing a unique class of chemically synthesised medicines based on its proprietary bicyclic peptide (Bicycle) product platform to address therapeutic needs unreachable with existing treatment modalities. Bicycles internal focus is in oncology, where the company is developing targeted cytotoxics (Bicycle Toxin Conjugates), targeted innate immune activators and T-cell modulators for cancers of high unmet medical need. Bicycles small size and exquisite targeting deliver rapid tumour penetration and retention while clearance rates and routes of elimination can be tuned to minimise exposure of healthy tissue and bystander toxicities. The companys lead program, BT1718, is being evaluated in a Phase I/IIa trial in collaboration with Cancer Research UK. The companys unique intellectual property is based on the work initiated at the MRC Laboratory of Molecular Biology in Cambridge, U.K., by the scientific founders of the company, Sir Gregory Winter, a winner of the Nobel Prize in Chemistry for his pioneering work in phage display of peptides and antibodies, and Professor Christian Heinis. Bicycle has its headquarters in Cambridge, U.K., with many key functions and members of its leadership team located in the biotech hub of Boston, Mass. For more information, visit www.bicycletherapeutics.com or follow us on Twitter at @Bicycle_tx.